10:30 AM EDT, 06/24/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Our 12-month target price is $963, based on a P/E of 93.6x applied to our 2027 EPS estimate. This is in line with Axon's average forward P/E during the last year. We note that there are significant risks of multiple contraction if growth rates start to disappoint. However, we continue to forecast strong growth (25%+) in sales and earnings throughout our forecast time horizon. Axon's product ecosystem includes TASER devices (newest TASER 10 with 45-foot range and 10 shots), connected sensors (body cameras, in-car systems, and drones), and AI-powered software solutions. With future contracted bookings of $9.9 billion and continued investment in R&D, Axon remains well positioned to capitalize on the growing demand for integrated public safety technology solutions while advancing its mission to protect life through innovative deterrence and safety tools. We are bullish on Axon's growth prospects in enterprise and international markets. We forecast adjusted EPS of $6.28 in 2025, $8.04 in 2026, and $10.29 in 2027.